Cochrane Review Group
Neonatal
210 systematic reviews in Neonatal ask 2,353 questions. 18.4% have no studies to answer them, 25.9% rest on very low certainty evidence and 20.3% reach moderate or high certainty.
Reviews
210
Questions
2,353
current versions
No studies
18.4%
Moderate or high
20.3%
No studies 432 · 18.4%Ungraded 99 · 4.2%Very low 609 · 25.9%Low 737 · 31.3%Moderate 385 · 16.4%High 91 · 3.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Salbutamol vs placebo Adverse effects of bronchodilators, including hypokalaemia, tachycardia, cardiac arrhythmia, tremor, hypertension and hyperglycaemia ‐ not reported · preterm infants (< 37 weeks GA) at risk of chronic lung disease Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Salbutamol vs placebo Pneumothorax · preterm infants (< 37 weeks GA) at risk of chronic lung disease Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane | no estimate extracted | 1 study · 173 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Pulmonary air leak, any (during first hospitalisation) Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | RR 2.56 [0.11, 59.75] | 1 study · 48 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Bronchopulmonary dysplasia (clinical definition) among survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Intraventricular haemorrhage grade III and IV Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | RR 2.56 [0.11, 59.75] | 1 study · 48 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Death (all causes) during the first hospitalisation Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | RR 0.17 [0.01, 3.37] | 1 study · 48 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Neurosensory disability in survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surfactant administration via laryngeal mask airway (S‐LMA) vs no surfactant administration Intraventricular haemorrhage grade III and IV Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | 1 study · 103 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs no surfactant administration Death (all causes) during the first hospitalisation Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | 1 study · 103 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs no surfactant administration Neurosensory disability in survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with the intent to rapidly extubate (InSurE) Intraventricular haemorrhage grade III and IV Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | 1 study · 50 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with the intent to rapidly extubate (InSurE) Neurosensory disability in survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Reviews 210
Routine monitoring of gastric residual for prevention of necrotising enterocolitis in preterm infants
CochraneSoF table
14 questions
Re‐feeding versus discarding gastric residuals to improve growth in preterm infants
CochraneSoF table
7 questions
Surfactant therapy guided by tests for lung maturity in preterm infants at risk of respiratory distress syndrome
CochraneSoF table
7 questions
Superoxide dismutase for bronchopulmonary dysplasia in preterm infants
CochraneSoF table
9 questions
Automated oxygen delivery for preterm infants with respiratory dysfunction
CochraneSoF table
12 questions
Hand hygiene for the prevention of infections in neonates
CochraneSoF table
10 questions
Musical and vocal interventions to improve neurodevelopmental outcomes for preterm infants
CochraneSoF table
12 questions
Continuous positive airway pressure (CPAP) for apnoea of prematurity
CochraneSoF table
15 questions
Higher versus lower protein intake in formula‐fed term infants
CochraneSoF table
14 questions
Methylxanthine for the prevention and treatment of apnea in preterm infants
CochraneSoF table
33 questions
Antiseptic solutions for skin preparation during central catheter insertion in neonates
CochraneSoF table
12 questions
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity
CochraneSoF table
32 questions
Doxapram for the prevention and treatment of apnea in preterm infants
CochraneSoF table
36 questions
Sucrose analgesia for heel‐lance procedures in neonates
CochraneSoF table
28 questions
Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates
CochraneSoF table
21 questions
Anti‐seizure medications for neonates with seizures
CochraneSoF table
55 questions
Systemic opioid regimens for postoperative pain in neonates
CochraneSoF table
13 questions
Opioids for procedural pain in neonates
CochraneSoF table
26 questions
Bubble devices versus other pressure sources for nasal continuous positive airway pressure in preterm infants
CochraneSoF table
6 questions
Prebiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
CochraneSoF table
6 questions
Non‐opioid analgesics for procedural pain in neonates
CochraneSoF table
10 questions
Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants
CochraneSoF table
14 questions
Positioning for lumbar puncture in newborn infants
CochraneSoF table
14 questions
Pharmacological interventions for the management of pain and discomfort during lumbar puncture in newborn infants
CochraneSoF table
7 questions
Delayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infants
CochraneSoF table
4 questions